CRA was retained by a pharmaceutical company to assist in settlement negotiations with a potential generic competitor. As part of this project, CRA prepared a flexible valuation model to estimate the expected profits from the perspective of the generic competitor under various assumptions. CRA also prepared a decision probability tree analysis to address issues related to litigation risk, acceptable date of generic entry and the impact of an authorized generic.
IP Literature Watch: May 2023
In this month’s IP Literature Watch we include a paper providing an overview of the proposed alternative dispute settlement frameworks under the Data Act and...